Sangamo Therapeutics (SGMO)
NASDAQ:SGMO
Top Page
Sangamo Therapeutics
(NASDAQ:SGMO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.30
▲(18.40% Upside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance (persistent losses, cash burn, and negative equity) and bearish technicals. Offsetting these, the latest earnings call highlighted substantial progress toward an accelerated-approval filing for ST-920 and meaningful capital raised, though the need for additional funding and dilution risk remain major constraints.
Positive Factors
Pivotal STAAR efficacy
Durable clinical efficacy in the STAAR registrational data — sustained positive eGFR slope at 52 and 104 weeks and functional improvements — supports using the Phase 1/2 dataset as an accelerated-approval basis. That clinical signal can materially de-risk approval and underpins a long-term shift from chronic ERT to a potential one‑time gene therapy for Fabry disease, improving commercial and clinical durability if approval and payer acceptance follow.
Negative Factors
Negative equity
The move to negative shareholders' equity is a structural red flag that reduces financial flexibility and creditworthiness. Negative equity limits borrowing capacity, increases reliance on external capital, and can complicate partnership negotiations and contract terms over months, forcing potentially dilutive financing or asset sales to restore a sustainable balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal STAAR efficacy
Durable clinical efficacy in the STAAR registrational data — sustained positive eGFR slope at 52 and 104 weeks and functional improvements — supports using the Phase 1/2 dataset as an accelerated-approval basis. That clinical signal can materially de-risk approval and underpins a long-term shift from chronic ERT to a potential one‑time gene therapy for Fabry disease, improving commercial and clinical durability if approval and payer acceptance follow.
Read all positive factors
Sangamo Therapeutics (SGMO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.52M
Dividend YieldN/A
Average Volume (3M)7.65M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-37.13%
EPS Growth40.47%
CountryUS
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding414,274,020
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit2.89
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$6.00Price Target Upside2300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$80.33M
Sangamo Therapeutics Business Overview & Revenue Model
Company Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulati...
How the Company Makes Money
Sangamo has historically generated most of its revenue from collaboration-related income rather than product sales. Key revenue streams have included (1) upfront payments received when entering new collaboration or license agreements; (2) research...
Sangamo Therapeutics Earnings Call Summary
Earnings Call Date:Mar 30, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The call balanced substantial clinical and regulatory progress — including positive pivotal Fabry data, a rolling BLA submission with clinical and nonclinical modules filed, manufacturing milestones, >$130M raised, Fast Track designation, and a strategic capsid license with a major partner — against material financial and timing risks. The company made important scientific and regulatory advances but continues to face unresolved long-term cash runway concerns, partnership delays, and CMC-driven timeline extensions that are critical to achieving approval and commercialization.Positive Updates
Positive STAAR registrational results (Fabry disease)
Top-line STAAR study results showed a positive mean annualized eGFR slope at 52 weeks across all study patients and sustained positive eGFR slope at 2 years for 19 patients, indicating improved/stabilized kidney function versus historical decline in Fabry disease. No percentage changes were disclosed.
Negative Updates
Unresolved long-term cash runway
Management reiterated that Sangamo has limited cash resources and that solving the long-term cash runway remains a top priority; completion of the BLA and continued operations are contingent on securing adequate additional funding.
Read all updates
Q4-2025 Updates
Positive
Negative
Positive STAAR registrational results (Fabry disease)
Top-line STAAR study results showed a positive mean annualized eGFR slope at 52 weeks across all study patients and sustained positive eGFR slope at 2 years for 19 patients, indicating improved/stabilized kidney function versus historical decline in Fabry disease. No percentage changes were disclosed.
Read all positive updates
Company Guidance
Management guided that Sangamo is pursuing accelerated approval for ST‑920 with a rolling BLA submission underway—nonclinical and clinical modules have been submitted, the companion diagnostic was accepted by CDRH, and CMC remains the critical path (process‑validation lots manufactured and tested with acceptable results, method validation complete and the first commercial lot produced), with completion of the BLA submission anticipated as early as this summer subject to securing additional funding; the FDA indicated a positive mean annualized eGFR slope at 52 weeks may serve as the primary basis for accelerated approval (positive at 1 year across all patients and at 2 years for 19 patients). Other numeric progress: 6 active clinical sites in the Phase I/II STAND study, Fast Track designation for ST‑503, a completed GLP toxicology study for ST‑506 (analysis ongoing), a third STAC‑BBB capsid license (including Eli Lilly for up to 5 CNS targets), 4 presentations at the WORLDSymposium, and more than $130 million raised since the start of 2025 via nondilutive license fees, milestone payments and equity financing—while management emphasized prudent cash management and that securing a Fabry commercialization partner remains their #1 focus.Sangamo Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 39.55M | 57.80M | 176.23M | 111.30M | 110.70M |
| Gross Profit | 39.55M | 57.80M | 176.23M | 99.19M | 110.70M |
| EBITDA | -100.40M | -89.09M | -96.80M | -189.17M | -165.70M |
| Net Income | -122.93M | -97.94M | -257.83M | -192.28M | -178.29M |
Balance Sheet | |||||
| Total Assets | 59.74M | 101.64M | 165.32M | 562.51M | 721.92M |
| Cash, Cash Equivalents and Short-Term Investments | 20.95M | 41.92M | 81.00M | 277.63M | 376.55M |
| Total Debt | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Total Liabilities | 74.01M | 78.86M | 82.43M | 267.55M | 346.58M |
| Stockholders Equity | -14.27M | 22.77M | 82.89M | 294.96M | 375.34M |
Cash Flow | |||||
| Free Cash Flow | -97.31M | -67.41M | -246.00M | -243.80M | -256.53M |
| Operating Cash Flow | -97.21M | -67.14M | -224.84M | -223.63M | -233.25M |
| Investing Cash Flow | -102.00K | 37.52M | 153.53M | 59.28M | 248.20M |
| Financing Cash Flow | 70.75M | 28.38M | 14.59M | 84.66M | 32.86M |
Sangamo Therapeutics Technical Analysis
Negative
0.25
Price Trends
0.38
Negative
0.41
Negative
0.49
Negative
Market Momentum
-0.04
Positive
33.01
Neutral
30.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.38, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 33.01 is Neutral, neither overbought nor oversold. The STOCH value of 30.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.
Sangamo Therapeutics Risk Analysis
Sangamo Therapeutics disclosed 57 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sangamo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $143.22M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $343.99M | -1.34 | -121.73% | ― | ― | -17.21% | |
50 Neutral | $186.35M | -3.95 | -977.67% | ― | ― | 17.36% | |
47 Neutral | $105.52M | -0.96 | -813.95% | ― | -37.13% | 40.47% | |
47 Neutral | $188.44M | -1.42 | -74.28% | ― | -19.00% | -2.72% |
* Healthcare Sector Average
SGMO
Sangamo Therapeutics
0.25
-0.47
-64.87%
CABA
Cabaletta Bio
3.09
2.00
183.49%
BDTX
Black Diamond Therapeutics
2.50
1.08
76.06%
ELTX
Elicio Therapeutics
10.13
5.06
99.80%
CRBU
Caribou Biosciences
1.95
1.09
126.74%
Sangamo Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sangamo Biosciences launches dilutive February 2026 financing
Negative
Feb 4, 2026
On February 3, 2026, Sangamo Therapeutics entered into an underwriting agreement with Cantor Fitzgerald and Wells Fargo Securities for an underwritten public offering of 35.19 million shares of common stock and pre-funded warrants for 17.79 millio...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Sangamo advances Fabry gene therapy with pivotal STAAR data
Positive
Feb 3, 2026
On February 3, 2026, Sangamo Therapeutics reported detailed clinical data from its registrational Phase 1/2 STAAR study of its Fabry disease gene therapy candidate isaralgagene civaparvovec (ST-920), covering 33 treated patients as of an April 10,...
Executive/Board Changes
Sangamo Biosciences Names Interim CFO After Officer Departure
Neutral
Feb 3, 2026
On February 2, 2026, Sangamo Biosciences’ principal financial officer, Prathyusha Duraibabu, departed the company, and effective February 3, 2026, Vice President of Finance and Corporate Controller, and current principal accounting officer, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.